Clinical Trial Update: Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96 [Phase 1, Phase 2]

View source ↗

Summary

Update on an ongoing phase 1/2 trial evaluating an autologous tumor-derived heat shock protein gp96 vaccine for hepatocellular carcinoma and pancreatic ductal a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• gp96 heat shock protein peptide complex vaccine (gp96 heat shock protein peptide complex)

Snippet

Sponsor: Cure&Sure Biotech Co., LTD | Conditions: Liver Cancer, Pancreatic Adenocarcinoma | Phase 1, Phase 2 | Status: UNKNOWN